This entire article is available in Full Text to registered users.

Improvement in Functional Outcomes With Adjunctive Aripiprazole Versus Placebo in Major Depressive Disorder: A Pooled Post Hoc Analysis of 3 Short-Term Studies

Tanya J. Fabian, PharmD, PhD; Zachary J. Cain, PharmD; Diane Ammerman, PharmD; James M. Eudicone, MS, MBA; Yan Tang, MS; Linda M. Rollin, PhD; Robert A. Forbes, PhD; Robert M. Berman, MD; and Ross A. Baker, PhD, MBA

ABSTRACT

Objective: To evaluate the effect of adjunctive aripiprazole to antidepressant therapy (ADT) on functional outcomes, as assessed by the Sheehan Disability Scale (SDS).

Method: A post hoc analysis of pooled data from 3 similarly designed randomized, placebo-controlled trials was conducted (CN138-139 [September 2004–December 2006], CN138-163 [June 2004–April 2006], and CN138-165 [March 2005–April 2008]). Patients with DSM-IV major depressive disorder who had a prior inadequate response to ADT received adjunctive aripiprazole or placebo to standard ADT. The change from baseline to endpoint on total SDS score and on individual SDS domains and the distributional categorical shifts of patient-reported severity of functional impairment on the SDS were assessed.

Results: Aripiprazole compared to placebo augmentation produced significant improvements in self-reported functioning levels in the SDS mean total score (–1.2 vs –0.7, P .001) and social life (–1.4 vs –0.7, P .001) and family life (–1.4 vs –0.7, P .001) domains. Additionally, a significant number of patients exhibited a shift from a severe/moderate level of impairment at baseline to a mild level of functional impairment after 6 weeks of adjunctive aripiprazole treatment compared with placebo in the SDS mean total score (P = .001) and social life (P .001) and family life (P = .001) scores.

Conclusions: Aripiprazole augmentation of standard antidepressant therapy resulted in significant improvements in both total and individual domains of functioning, as assessed by the SDS, with significant categorical shifts from severe/moderate to mild levels of functioning compared with placebo augmentation.

Trial Registration: ClinicalTrials.gov identifiers: NCT00095823, NCT00095758, and NCT00105196

Prim Care Companion CNS Disord 2012;14(6):doi:10.4088/PCC.12m01394

Submitted: April 11, 2012; accepted July 2, 2012.

Published online: Decmber 20, 2012.

Corresponding author: Tanya J. Fabian, PharmD, PhD, Ste 430 WPIC, 3811 O’Hara St, Pittsburgh, PA 15213 (fabiant@upmc.edu).